Related Experiment Videos
Glucocorticoid-induced osteoporosis: a cross-sectional study
D W Brandli1, G Golde, M Greenwald
1Osteoporosis Medical Center, Beverly Hills, CA 90210.
Steroids
|October 1, 1991
Summary
Glucocorticoid therapy significantly reduces bone mineral density (BMD) in the hip, spine, and radius. Short height and low weight are key factors associated with reduced bone mass in patients on glucocorticoids.
Area of Science:
- Endocrinology
- Rheumatology
- Pulmonology
Background:
- Glucocorticoids are widely used for rheumatic and lung diseases.
- Long-term glucocorticoid use is associated with decreased bone mineral density (BMD).
Purpose of the Study:
- To assess the impact of glucocorticoids on hip bone density.
- To investigate the correlation between glucocorticoid therapy and BMD.
- To determine the incidence of hypercalciuria in patients on glucocorticoids.
Main Methods:
- Dual- and single-photon absorptiometry were used to measure BMD in the hip, spine, and radius.
- Patient data included current and cumulative glucocorticoid doses and duration of therapy.
- Hypercalciuria was assessed and compared to age- and sex-matched controls.
Main Results:
- Patients on glucocorticoids showed significantly reduced BMD in the spine, hip, and radius compared to controls.
- Short height and low weight were strongly correlated with low bone mass at the hip and spine.
- A high incidence of hypercalciuria (30%) was observed in the study population.
Conclusions:
- Glucocorticoids decrease bone density at the hip, in addition to the spine and radius.
- Hypercalciuria may play a role in glucocorticoid-induced osteoporosis.
- Further research is needed to explore therapeutic implications of hypercalciuria.